Citigroup Maintains Neutral on Boston Scientific, Lowers Price Target to $44

Benzinga · 10/29 19:21
Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Neutral and lowers the price target from $48 to $44.